After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the second quarter. 

In this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy break down the numbers behind the industry’s second-quarter performance.

Among U.S. pharma heavyweights, J&J, AbbVie, Pfizer, Regeneron, Bristol Myers Squibb and Biogen each eked out gains this past quarter. Their results varied, with individual stories worth highlighting at each of these major companies.

Beyond earnings, Sagonowsky and Dunleavy also discuss the growing competition in diabetes and obesity treatments between Eli Lilly and Novo Nordisk, as well as Merck’s rising financial reliance on its blockbuster cancer drug Keytruda, among other topics. 

To learn more about the topics in this episode: 
Several US pharma giants stage Q2 sales turnaround after subpar results earlier in year
The battle of the obesity drug heavyweights
7 top pharmas posted revenue declines in Q1. The common thread? All are US firms
Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview

 

After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the second quarter.&nbsp;
In this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy break down the numbers behind the industry&rsquo;s second-quarter performance.
Among U.S. pharma heavyweights, J&amp;J, AbbVie, Pfizer, Regeneron, Bristol Myers Squibb and Biogen each eked out gains this past quarter. Their results varied, with individual stories worth highlighting at each of these major companies.
Beyond earnings, Sagonowsky and Dunleavy also discuss the growing competition in diabetes and obesity treatments between Eli Lilly and Novo Nordisk, as well as Merck&rsquo;s rising financial reliance on its blockbuster cancer drug Keytruda, among other topics.&nbsp;
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/pharma/q2-several-us-companies-rebound-after-subpar-results-q1">Several US pharma giants stage Q2 sales turnaround after subpar results earlier in year</a></li>
<li><a href="https://www.fiercepharma.com/pharma/battle-obesity-drug-heavyweights">The battle of the obesity drug heavyweights</a></li>
<li><a href="https://www.fiercepharma.com/pharma/except-juggernaut-eli-lilly-several-us-drugmakers-saw-revenue-declines-q1">7 top pharmas posted revenue declines in Q1. The common thread? All are US firms</a></li>
<li><a href="https://www.fiercepharma.com/pharma/biopharma-briefing-q1-trends-gene-therapy-updates-and-asco-preview">Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview</a></li>
</ul>
&nbsp;

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement